Frazier Life Sciences Public Fund, L.P. 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-07 2:34 pm Purchase | 2024-11-05 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 4,887,867 10.000% | 1,200,000 (+32.54%) | Filing |
| 2024-02-22 1:22 pm Purchase | 2024-02-20 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 3,687,867 8.900% | 105,573 (+2.95%) | Filing |
| 2023-12-14 1:33 pm Purchase | 2023-12-12 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 3,582,294 10.400% | 343,435 (+10.60%) | Filing |
| 2022-12-30 2:15 pm Purchase | 2022-12-28 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 3,238,859 9.500% | 1,666,667 (+106.01%) | Filing |
| 2022-01-31 5:00 pm Purchase | 2022-01-26 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 1,572,192 6.400% | 303,463 (+23.92%) | Filing |
| 2021-12-30 4:33 pm Purchase | 2021-12-21 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 1,268,729 5.200% | 1,268,729 (New Position) | Filing |